MRI for restaging pancreatic cancer
Abstract
Pancreatic adenocarcinoma is a tumor with a dismal prognosis, as the majority of patients are diagnosed when the tumor is not resectable. Neoadjuvant treatment has significantly improved prognosis, but assessing treatment response can be challenging for radiologists. Given the fibrotic nature of the primary tumor, differentiating between residual viable tumor and fibrotic response can be difficult. MRI can have a role in reassessing the primary tumor and disease spread. In this review, we discuss MR techniques that can be used for this assessment, including routinely used sequences (e.g., DWI) and sequences that are not yet routinely included in pancreatic protocols (e.g., T1 mapping, ECV imaging, and USPIO contrast for nodal staging).
Key Points: Question Imaging assessment of the response of pancreatic adenocarcinoma to neoadjuvant treatment is difficult and still has limited accuracy.
Findings Different MRI sequences and techniques have been suggested as possibly improving this assessment, reflecting on better patient management.
Critical relevance statement We summarize the available evidence on MRI for restaging pancreatic carcinoma after neoadjuvant treatment.
Related
- [18F] FDG-PET/MRI Performance in Head and Neck Cancers at Initial Staging, Restaging, and Follow-up
- An Atypical Abdominal Presentation of Pancreatic Panniculitis in a Patient With Suspected Pancreatic Cancer: A Case Report
- Aldehyde Dehydrogenase 2 Activity Assessed Using the Acetaldehyde Breath Test Is Associated with Benign Pancreatic Disease and Pancreatic Cancer: A Case–Control Study
- Hemospray for Pancreatic Cancer-Related Gastric Bleeding
- Multiple R1 margins are associated with shorter overall survival: national register-based study on pancreatic cancer
BibTeX
@article{zamboni2026restaging,
title = {{MRI for restaging pancreatic cancer}},
author = {Giulia A. Zamboni and Federica Omboni and Irene Panozzo},
journal = {Insights into imaging},
year = {2026},
month = oct,
doi = {10.1186/s13244-026-02422-1},
url = {https://europepmc.org/article/PMC/PMC13661870},
note = {CC BY},
}
RIS
TY - JOUR
TI - MRI for restaging pancreatic cancer
AU - Giulia A. Zamboni
AU - Federica Omboni
AU - Irene Panozzo
PY - 2026
DA - 2026/10/13
JO - Insights into imaging
DO - 10.1186/s13244-026-02422-1
UR - https://europepmc.org/article/PMC/PMC13661870
AB - Pancreatic adenocarcinoma is a tumor with a dismal prognosis, as the majority of patients are diagnosed when the tumor is not resectable. Neoadjuvant treatment has significantly improved prognosis, but assessing treatment response can be challenging for radiologists. Given the fibrotic nature of the primary tumor, differentiating between residual viable tumor and fibrotic response can be difficult. MRI can have a role in reassessing the primary tumor and disease spread. In this review, we discuss MR techniques that can be used for this assessment, including routinely used sequences (e.g., DWI) and sequences that are not yet routinely included in pancreatic protocols (e.g., T1 mapping, ECV imaging, and USPIO contrast for nodal staging). Key Points: Question Imaging assessment of the response of pancreatic adenocarcinoma to neoadjuvant treatment is difficult and still has limited accuracy. Findings Different MRI sequences and techniques have been suggested as possibly improving this assessment, reflecting on better patient management. Critical relevance statement We summarize the available evidence on MRI for restaging pancreatic carcinoma after neoadjuvant treatment.
SN - 1869-4101
ER -